Glucagon-Like Peptide 2 Receptor (GLP-2 Receptor or GLP2R) - Pipeline Review, H1 2016

Published: May, 2016 | Pages: 49 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Glucagon-Like Peptide 2 Receptor (GLP-2 Receptor or GLP2R) - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Glucagon-Like Peptide 2 Receptor (GLP-2 Receptor or GLP2R) - Pipeline Review, H1 2016', provides in depth analysis on Glucagon-Like Peptide 2 Receptor (GLP-2 Receptor or GLP2R) targeted pipeline therapeutics. 

The report provides comprehensive information on the Glucagon-Like Peptide 2 Receptor (GLP-2 Receptor or GLP2R), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Glucagon-Like Peptide 2 Receptor (GLP-2 Receptor or GLP2R) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Glucagon-Like Peptide 2 Receptor (GLP-2 Receptor or GLP2R)
- The report reviews Glucagon-Like Peptide 2 Receptor (GLP-2 Receptor or GLP2R) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Glucagon-Like Peptide 2 Receptor (GLP-2 Receptor or GLP2R) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Glucagon-Like Peptide 2 Receptor (GLP-2 Receptor or GLP2R) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Glucagon-Like Peptide 2 Receptor (GLP-2 Receptor or GLP2R) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Glucagon-Like Peptide 2 Receptor (GLP-2 Receptor or GLP2R)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Glucagon-Like Peptide 2 Receptor (GLP-2 Receptor or GLP2R) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Glucagon-Like Peptide 2 Receptor (GLP-2 Receptor or GLP2R) Overview 6
Therapeutics Development 7
Glucagon-Like Peptide 2 Receptor (GLP-2 Receptor or GLP2R) - Products under Development by Stage of Development 7
Glucagon-Like Peptide 2 Receptor (GLP-2 Receptor or GLP2R) - Products under Development by Therapy Area 8
Glucagon-Like Peptide 2 Receptor (GLP-2 Receptor or GLP2R) - Products under Development by Indication 9
Glucagon-Like Peptide 2 Receptor (GLP-2 Receptor or GLP2R) - Pipeline Products Glance 10
Late Stage Products 10
Early Stage Products 11
Glucagon-Like Peptide 2 Receptor (GLP-2 Receptor or GLP2R) - Products under Development by Companies 12
Glucagon-Like Peptide 2 Receptor (GLP-2 Receptor or GLP2R) - Therapeutics Assessment 14
Assessment by Monotherapy/Combination Products 14
Assessment by Mechanism of Action 15
Assessment by Route of Administration 16
Assessment by Molecule Type 17
Glucagon-Like Peptide 2 Receptor (GLP-2 Receptor or GLP2R) - Companies Involved in Therapeutics Development 19
Naia Limited 19
Shire Plc 20
Tasly Pharmaceutical Group Co., Ltd. 21
Zealand Pharma A/S 22
Glucagon-Like Peptide 2 Receptor (GLP-2 Receptor or GLP2R) - Drug Profiles 23
FE-203799 - Drug Profile 23
Product Description 23
Mechanism Of Action 23
R&D Progress 23
GXG-8 - Drug Profile 24
Product Description 24
Mechanism Of Action 24
R&D Progress 24
NB-1002 - Drug Profile 25
Product Description 25
Mechanism Of Action 25
R&D Progress 25
teduglutide (recombinant) - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
ZP-1848 - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
ZPGG-23 - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
ZPGG-72 - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
Glucagon-Like Peptide 2 Receptor (GLP-2 Receptor or GLP2R) - Dormant Projects 35
Glucagon-Like Peptide 2 Receptor (GLP-2 Receptor or GLP2R) - Featured News & Press Releases 36
Feb 15, 2016: Zealand doses the first patients with ZP1848 for short bowel syndrome, advancing the second of its proprietary specialty medicines into Phase II development in 2016 36
Sep 17, 2015: Zealand advances its proprietary, long-acting GLP-2 analogue, ZP1848, into clinical Phase II development for the treatment of Short Bowel Syndrome 36
Apr 06, 2015: Shire Comments on USPTO Petition Related to GATTEX 37
Nov 24, 2014: Teduglutide Granted Orphan Drug Designation in Japan 37
Jun 30, 2014: FDA Approves Updated Labeling for Gattex (Teduglutide) for Injection to Include Long-Term Data 38
Jun 17, 2014: Zealand presented new data on GLP-1/GLP-2 novel peptide therapeutics from its preclinical diabetes pipeline at the American Diabetes Association's (ADA) 74th Scientific Sessions 39
Jan 02, 2014: NPS Pharmaceuticals Initiates Global Registration Study of Teduglutide in Pediatric Patients with Short Bowel Syndrome 39
Nov 13, 2013: NPS Pharmaceuticals Announces FDA Acceptance of Supplemental New Drug Application for Gattex for Injection 40
Oct 14, 2013: New Data from STEPS 2 Support the Long Term Use of Gattex for Injection in Adult Patients with Short Bowel Syndrome 41
Oct 02, 2013: NPS Pharmaceuticals Reports Gattex STEPS 2 Study to be Presented at American College of Gastroenterology Meeting 42
Jan 30, 2013: New Peer-reviewed Publication Offers Guidance For Integrating Gattex For Injection Into Management Of Short Bowel Syndrome 43
Jan 02, 2013: ThriveRx Receives Limited Distribution Rights To NPS Pharma's Gattex For Treatment Of Short Bowel Syndrome In Adults 45
Dec 27, 2012: Coram Specialty Infusion Services To Provide NPS Pharma's Gattex For Treatment Of Short Bowel Syndrome 45
Dec 21, 2012: NPS Pharma's Gattex Receives FDA Approval For Treatment Of Short Bowel Syndrome 46
Nov 29, 2012: NPS Pharma Announces Publication Of Pivotal Phase III Study Of Gattex In Short Bowel Syndrome-intestinal Failure Patients 47
Appendix 48
Methodology 48
Coverage 48
Secondary Research 48
Primary Research 48
Expert Panel Validation 48
Contact Us 48
Disclaimer 49

List of Tables

Number of Products under Development for, H1 2016 7
Number of Products under Development by Therapy Area, H1 2016 8
Number of Products under Development by Indication, H1 2016 9
Comparative Analysis by Late Stage Development, H1 2016 10
Comparative Analysis by Early Stage Products, H1 2016 11
Number of Products under Development by Companies, H1 2016 12
Products under Development by Companies, H1 2016 13
Assessment by Monotherapy/Combination Products, H1 2016 14
Number of Products by Stage and Mechanism of Action, H1 2016 15
Number of Products by Stage and Route of Administration, H1 2016 16
Number of Products by Stage and Molecule Type, H1 2016 18
Pipeline by Naia Limited, H1 2016 19
Pipeline by Shire Plc, H1 2016 20
Pipeline by Tasly Pharmaceutical Group Co., Ltd., H1 2016 21
Pipeline by Zealand Pharma A/S, H1 2016 22
Dormant Projects, H1 2016 35